First data for AJM-347 shows promise for the treatment of IBD
May 26, 2021
EA Pharma has presented the pharmacological characterization of the company's oral alpha4beta7 integrin antagonist AJM-347, in development as a treatment for inflammatory bowel disease (IBD).
